Last reviewed · How we verify
Lactobacillus Species
Lactobacillus species are live beneficial bacteria that colonize the gut microbiome and promote digestive health and immune function.
Lactobacillus species are live beneficial bacteria that colonize the gut microbiome and promote digestive health and immune function. Used for Digestive health and gut microbiome support, Gastrointestinal disorders and dysbiosis.
At a glance
| Generic name | Lactobacillus Species |
|---|---|
| Sponsor | Vedic Lifesciences Pvt. Ltd. |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Lactobacillus species are probiotic organisms that establish themselves in the gastrointestinal tract, where they produce lactic acid and other metabolites that inhibit pathogenic bacteria, strengthen the intestinal barrier, and modulate local and systemic immune responses. These organisms compete with harmful microbes for nutrients and adhesion sites, while also producing short-chain fatty acids and other bioactive compounds that support gut health and overall wellness.
Approved indications
- Digestive health and gut microbiome support
- Gastrointestinal disorders and dysbiosis
Common side effects
- Gastrointestinal bloating or gas
- Mild abdominal discomfort
- Transient diarrhea
Key clinical trials
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- Er,Cr:YSGG Laser Versus Conventional Preparation for Minimally Invasive Caries Removal (NA)
- Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis (NA)
- Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis (PHASE2)
- Effect of Probiotic Supplementation on Endothelial Function II (NA)
- Microbiological Effect of 0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis. (PHASE4)
- Probiotic (LGG) for Veterans With PTSD (PHASE2)
- Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus Species CI brief — competitive landscape report
- Lactobacillus Species updates RSS · CI watch RSS
- Vedic Lifesciences Pvt. Ltd. portfolio CI